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Leaders in the fields of Temporomandibular Disorders (TMD) and its accompanying overlapping pain conditions
presented their latest findings at the Seventh Scientific Meeting of The TMJ Association, September 7–9, 2014, in
Bethesda, MD. The meeting was co-sponsored by The TMJ Association and the National Institutes of Health. Topics of
the scientific sessions included epidemiology and diagnostic criteria, basic mechanisms of chronic pain including the
genetic and epigenetic basis of chronic pain, and the development of novel drugs for treatment of these conditions.
Discussions were directed toward formulating a set of recommendations to advance research in this field.Epidemiology and diagnostics of TMD and
overlapping pain conditions
Temporomandibular disorders are characterized by pain
and dysfunction in one or both jaw joints and/or their
associated bone, cartilage, and muscle tissues. Mild cases
may resolve over time, but more severe and chronic
cases occur with a number of other pain conditions at a
higher frequency than would be expected by chance. These
overlapping pain conditions include chronic headache,
endometriosis, fibromyalgia, interstitial cystitis/painful
bladder syndrome, irritable bowel syndrome, low back
pain, myalgic encephalomyelitis/chronic fatigue syndrome,
and vulvodynia. These disorders predominantly affect
women in their child-bearing years, giving rise to mod-
erate to severe pain and dysfunction in individuals over
the course of a lifetime.
The presentations at the meeting emphasized that the
diagnosis and treatment of TMD and overlapping pain
conditions has progressed in very small increments over
the past 50 years, citing at least four reasons: 1. TMD is
currently associated with dentistry; however research
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rently, neither physicians nor dentists are effectively trained
to address TMD. As a result there are no scientifically
based standards of care or best practices. 2. The safety and
effectiveness of any of the more than 50 treatments cur-
rently prescribed are unknown and in some cases can lead
to iatrogenic complications that worsen the condition. 3.
TMD and its overlapping pain conditions are stigmatized
and patients, mostly female, are often not taken seriously.
4. The research, whether epidemiologic, basic, clinical or
translational has been compartmentalized, focusing largely
on the end organ affected. This has greatly hampered the
sharing of diagnostic approaches and collaborative research
which might lead to fresh insights into mechanisms and
potential therapies.
Status reports on two major clinical studies were
presented. The OPPERA (Orofacial Pain: Prospective
Evaluation and Risk Assessment) study is a large, pro-
spective study designed to identify risk factors for the
development of TMD. Results of this study indicated
that the observed rate of first-onset TMD in 2,737 par-
ticipants with no history of TMD at enrollment was
3.5% per year. However, those who reported suffering
from other pain conditions at the time of enrollment
developed TMD at a significantly higher rate. The large-
scale MAPP research network (Multidisciplinary Approach
to the Study of Chronic Pelvic Pain) phenotyping study,
is focused on characterization of patients with urologicentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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bladder syndrome) using multiple analytic measures
including biomarkers, questionnaires, quantitative sen-
sory testing (e.g., measuring pain threshold), and other
neurobiological assessments. The goal of this multiple-
level analysis is the identification of distinct patient
subgroups, which might then lead to more targeted and
improved treatment.
Emerging from the presentations and discussions was
a critical need for resources to support research to eluci-
date the causes and mechanisms underlying TMD and
overlapping pain conditions. Attendees urged that case
definitions of these disorders be developed that conform
to current scientific findings.Basic and clinical mechanistic studies in
neuroscience and genomics
Multiple speakers discussed the diverse and interrelated
mechanisms of TMD and chronic pain phenomena in
general. Studies of pain processed by peripheral nociceptors
(nociceptive pain) were presented showing that prolonged
nociceptor activation leads to a peripheral sensitization
consisting of increased action potential firing and neuro-
transmitter release in the dorsal horn. This peripheral
sensitization in turn results in heightened excitability by
dorsal horn neurons, known as central sensitization. The
enhanced depolarization of these neurons causes recruit-
ment of NMDA glutamate receptors leading to hyperalge-
sia and allodynia. In contrast, neuropathic pain produced
by peripheral nerve lesions was shown to stimulate micro-
glia in the dorsal horn with the release of modulators such
as brain-derived neurotrophic factor, causing disinhibition
of GABA/glycine inhibitory neurons. This in turn leads to
central sensitization, similar to that observed in nocicep-
tive pain.
Several investigators presented evidence that TRP ion
channels, TRPV4 and TRPV1 in particular, are key media-
tors in pain transduction and peripheral sensitization in
the trigeminal ganglion sensory neurons. It was proposed
that TRP receptors should therefore be considered as
potential drug targets for analgesics specifically targeting
TMD and other related trigeminal pain disorders.
Also presented were novel observations showing that
young patients with several types of chronic pain syn-
dromes including fibromyalgia exhibit small-fiber poly-
neuropathies (SFPN) that can be objectively identified by
skin biopsy. A novel, non-invasive confocal microscopy
technique was presented for assessment of small fiber
neuropathies such as reduced nerve length which is
commonly found in fibromyalgia and other chronic pain
conditions. Not only of diagnostic importance, these stud-
ies also suggested that early-onset SPFN has novel causes
that can be treated by immunomodulatory therapy.Discussions yielded a general consensus to broaden
research in this area to advance understanding of the
mechanisms leading to the chronicity of pain. Given the
complexity of TMD and overlapping pain conditions, at-
tendees recommended that there be better integration
and coordination of research on all these conditions.
Genetics, epigenetics, and functional genomics of
TMD and overlapping pain conditions
Genome wide association studies (GWAS) conducted by
OPPERA and MAPP investigators and reported at the
meeting, have begun to reveal novel polymorphisms
associated with chronic pain conditions. In contrast,
work has only begun to assess genomic DNA modifica-
tions induced by environmental stressors that alter gene
expression (i.e., epigenetics). One novel study presented
used a neuropathic pain model (mouse spared nerve
injury) to assess the effects of chronic pain on DNA
methylation in the brain. After six months, methylation
in prefrontal cortex and thalamus was reduced (in a
reversible manner) suggesting a potential mechanism for
changes in gene expression induced by chronic pain.
Another study indicated that long-term opioid use led to
increased DNA methylation associated with increased
pain, thus offering an explanation for the development
of opioid tolerance.
Attendees noted that the application of genomic scale
approaches for the study of chronic pain requires the
integration of large amounts of diverse types of pheno-
typic and genomic/sequence data. Intriguing work was
presented on the construction of a global Bayesian causal
network using genetic, epigenetic, and transcriptomic data
to gain valuable insights into disease mechanisms and
progression. It was clear that such quantitative predictive
network models would be critical to advance this line of
research.
Presenters discussed the use of exciting new technolo-
gies for gene editing, such as ZFN, TALE, and CRISPR/
Cas9 methods to engineer both protein-based and RNA-
guided transcriptional activators and repressors targeted
to human genes that are already linked to pain pathways.
An important research challenge in this field will be
the development of novel methods for experimental and
therapeutic delivery of engineered DNA-binding proteins.
In general, participants recommended that research be
expanded to obtain molecular correlates of localized versus
comorbid generalized chronic pain, anxiety, and depression.
Genomic DNA and RNA deep sequencing is necessary to
identify sequence variants and DNA methylation patterns
that are associated with risk for overlapping pain condi-
tions. Further, attendees saw a strong need to develop novel
analytical tools to advance discovery in this field and for
researchers to acquire and apply cutting-edge tools for
targeted genome and epigenome editing.
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Potential therapeutic pathways were presented by several
investigators. One study targeted the inositol triphosphate
receptor-1 by overexpression of an allosteric inhibitor,
carbonic anhydrase-8 (Car8). This gene therapy resulted
in blockade of the thermal hyperalgesia and mechanical
allodynia exhibited in a Car8 null mutant mouse model.
Another promising target was shown to be the metabotro-
pic glutamate receptor 5. Preclinical studies on a negative
allosteric modulator of this receptor, fenobam, have been
encouraging, and it was proposed as a viable candidate for
clinical trials as an analgesic.
Ranking among the highest priorities to emerge from the
discussions at the meeting was a recommendation for the
rapid development of novel, non-opioid, mechanistically
based therapeutic agents for the treatment of the over-
lapping pain conditions under discussion. In this regard,
participants recommended that efforts be broadened to
identify novel molecular pathways and therapeutic targets
that are amenable to manipulation and consequently
can alter chronic pain modalities. Sensitive to research
involving genome editing and other novel therapeutic
approaches, attendees recommended that workshops be
convened to address ethical issues and include patients,
scientists, clinicians, legal experts, and ethicists.
Conclusion
The Seventh Scientific Meeting of The TMJ Association
focused on genetic, epigenetic, and mechanistic research
using novel approaches. In addition to the participation
of distinguished investigators from across the globe, the
meeting was also attended by patients and advocates
who were able to effectively and poignantly describe their
long-time suffering and frustrations to the audience. Staff
from a number of NIH Institutes and Centers attended
the meeting and presented their view on how to address
the challenges to translational research in this area and
how their efforts might be coordinated. The broad focus
of the meeting allowed for new interactions and fruitful
discussions which will lead to new and innovative insights
into the treatment of chronic pain conditions in the near
future. To expedite progress, scientists and clinicians must
work together with the private sector and federal agencies
to build the infrastructure required for the recommended
research and for its translation into clinical practice. NIH
was urged to conduct a feasibility/cost analysis study to
determine the funding and resources needed to support
proposed epidemiological, mechanistic and genomic/
epigenomic discovery research, together with new transla-
tional initiatives. This information could serve as a blue-
print for the public, patient advocacy organizations,
individual scientists and their professional organizations
to alert Congress to the enormity of the chronic pain
problem in the United States and the need to increaseresearch funding on these chronic pain conditions. Re-
search will result in improving the quality of health care
and lives of the millions of people suffering.
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